MTA1表达与中国肺癌患者预后关系的meta分析

Relationship between MTA1 Expression and Prognosis of Chinese Lung Cancer Patients: A Meta-analysis

背景与目的已有的研究表明:在多种恶性肿瘤中发现转移相关蛋白1(metastasis associated protein1,MTA1)发挥着促进肿瘤侵袭与转移的作用,且与肿瘤患者预后不佳有关。目前MTA1在肺癌中的预后作用仍有争议,故我们采用meta分析的方法评估其在肺癌患者中的预后价值。方法通过计算机检索PubMed、Embase、万方数据库、中国生物医学文献数据库、中国知网等数据库,收集纳入研究MTA1表达与肺癌预后关系的文献及相关数据,采用Stata 12.0软件进行数据分析,合并值为风险比(hazard ratio,HR)。结果总共纳入8项研究共712例中国肺癌患者,对这些研究进行异质性检验,发现存在异质性(I^2=59.0%,P=0.017),故采用随机效应模型进行数据合并得HR=2.07(95%CI:1.42-3.02,P<0.001)。同时分层分析显示在非小细胞肺癌(non-small cell lung cancer,NSCLC)中各研究无明显异质性(I^2=47.0%,P=0.093),采用固定效应模型合并得HR=1.66(95%CI:1.27-2.18,P<0.001)。结论 MTA1高表达可能是中国NSCLC患者预后不良的一个指标,在肺癌及小细胞肺癌中的预后价值尚缺乏证据。

Background and objective It has been proven that metastasis associated protein 1 （MTA1） was correlated with tumor invasion and migration and poor prognosis of several malignant carcinomas. The prognostic role of MTA1 expression in lung cancer remained controversial, we performed this meta-analysis to assess the prognostic value of MTA1 expression in lung cancer. Methods A systematic literature search was conducted to identify eligible studies which dealing with the relationship between MTA1 expression and prognosis of lung cancer in PubMed, Era- base, Wanfang databases, China Biology Medicine disc and China National Knowledge Infrastructure. The pooled hazard ratio （HR） were used to assess the relationship between MTA1 expression and prognosis of lung cancer. All data were analysed using the Stata 12.0 software. Results A total of 712 Chinese lung cancer patients from 8 studies were included in this meta-analysis. There was significant heterogeneity existed in these studies （I2=59.0%, P=0.017）, so we used a random effects model to calculate the pooled HR=2.07 （95%CI： 1.42-3.02, P〈0.001）. At the same time, we observed through stratified analysis by histology that there was no significant heterogeneity in non-small cell lung cancer （NSCLC）, and the fixed effects model was used to calculate the pooled HR=1.66 （95%CI： 1.27-2.18, P〈0.001）. Conclusion Overexpression of MTA1 could be a marker of poor prognosis in Chinese NSCLC patients, but not in lung cancer or small cell lung cancer. Additional studies with larger samples and well-designed were required to derive the more precise outcome.